Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDE574 + fulvestrant
- Development stage
- Phase 1
- Lead developer
- IDEAYA Biosciences
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
IDE574 + fulvestrant is an investigational combination regimen consisting of IDE574, an oral small-molecule dual inhibitor of the lysine acetyltransferases KAT6 and KAT7, and fulvestrant, an intramuscularly administered selective estrogen receptor degrader (SERD). Developed by IDEAYA Biosciences, this combination is being evaluated in a Phase 1/2 clinical trial (NCT07540572) for the treatment of patients with locally advanced or metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. By simultaneously inhibiting KAT6/KAT7-mediated epigenetic transcription and estrogen receptor signaling, the combination aims to overcome endocrine therapy resistance and drug tolerance in ER+/HER2- breast cancer.
- Other names
- IDE574 + fulvestrantIDE574 and fulvestrantIDE-574 and fulvestrantIDE 574 and fulvestrantfulvestrant + IDE574fulvestrant and IDE574
02
Targets
ESR1 (ERα)KAT6A (Lysine acetyltransferase 6A)KAT6B (Histone acetyltransferase KAT6B)KAT7 (Lysine acetyltransferase 7)
Beyond the preview
Go deeper on IDE574 + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDE574 + fulvestrant.